Calquence and Nifedical XL
Determining the interaction of Calquence and Nifedical XL and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:NIFEdipine may increase the blood levels of acalabrutinib in some patients. This may increase side effects such as nausea, vomiting, diarrhea, abdominal pain, hemorrhage, abnormal heart rhythm, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. Talk to your doctor if you have any questions or concerns. You may need a dose adjustment or more frequent monitoring to safely use both medications. Contact your doctor if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of acalabrutinib, which is primarily metabolized by the isoenzyme. When acalabrutinib was administered with the potent CYP450 3A4 inhibitor itraconazole (200 mg once daily for 5 days) in healthy subjects, acalabrutinib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 3.9- and 5.1-fold, respectively. Physiologically based pharmacokinetic (PBPK) simulations showed that moderate CYP450 3A4 inhibitors (erythromycin, fluconazole, diltiazem) increased acalabrutinib Cmax and AUC by 2- to nearly 3-fold.
MANAGEMENT: Caution is advised when acalabrutinib is used with CYP450 3A4 inhibitors. Patients should be monitored for increased adverse effects such as nausea, vomiting, diarrhea, hemorrhage, infection, cytopenias, and atrial fibrillation or flutter, and the acalabrutinib dosage adjusted as necessary.
- "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.
Generic Name: nifedipine
Brand name: Adalat CC, Afeditab CR, Nifediac CC, Nifedical XL, Procardia, Procardia XL, Adalat
Synonyms: Nifedical XL (Oral)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Calquence-Nifedipine
- Calquence-Nifedipine Capsules
- Calquence-Nifedipine Extended-Release Tablets
- Calquence-Niferex
- Calquence-Niferex Elixir
- Calquence-Night Cast R Topical
- Nifedical XL-Caltrate
- Nifedical XL-Caltrate 600+D
- Nifedical XL-Caltrate 600+D Soft Chews
- Nifedical XL-Cambia
- Nifedical XL-Camila
- Nifedical XL-Campath